PSA-Activated Prodrug: Precision Therapy for Prostate Cancer
Prostate Cancer Targeting Peptide
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
This innovative prostate cancer therapy uses a dual-peptide system to create prodrugs selectively activated by prostate-specific antigen (PSA), a marker highly expressed in prostate cancer cells. The system ensures precise drug delivery, minimizing side effects and increasing treatment efficacy. Applications include targeted prostate cancer therapy, diagnostic imaging, and personalized medicine. It offers a significant therapeutic advance by optimizing drug activation and reducing off-target activity. A PCT patent (WO2024036358A1) has been filed, ensuring the protection of this novel approach.
IP Type or Form Factor: Patent Pending; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
